Biomarkers to Predict Cancer Therapy-related Cardiotoxicity

Inclusion Criteria:

• 18 years of age or older

• Treated for any malignancy with any type of chemotherapy including oral, parenteraltherapy and immunotherapy

• One of the following:

• Diagnosed with cardiotoxicity defined as; cardiomyopathy, symptomatic heartfailure, asymptomatic reduced systolic function, acute coronary syndrome,myocardial infarction, critical limb ischemia, cardiac arrhythmias ormyocarditis possibly related to prior cancer treatment

• Completed chemotherapy with no cardiotoxicity at least two years post treatment

• Patients with cancer who will be initiating systemic therapy with potentiallycardiotoxic medications. This will include chemotherapy, immunotherapy,targeted therapy that have been associated with cardiac toxicity

• An understanding of the protocol and its requirements, risks, and discomforts

• The ability and willingness to sign an informed consent

Exclusion Criteria:

• Inability on the part of the patient to understand the informed consent or becompliant with the protocol